Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SANGUINATE in acute severe anemia
NCT02754999Phase 1Completed
- Sponsor
- Prolong Pharmaceuticals
- Start
- Mar 2016
- Primary completion
- May 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Sanguinate in anaemia, sponsored by Prolong Pharmaceuticals. Primary endpoint: Number and severity of adverse events within 24-hours of each SANGUINATE infusion. Started Mar 2016; status: completed.
02
Drugs
Sanguinate
03
Conditions
anaemia
Beyond the preview
Go deeper on NCT02754999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02754999.